Background. Linezolid is an effective second-line drug for the treatment of drug-resistant tuberculosis (DR-TB), but it is often associated with hematological adverse effects. Patient characteristics such as age, residence, body mass index, serum albumin level, HIV status, diabetes mellitus, and treatment duration are suspected to contribute to these events. This study aimed to analyze the rela…